The first intestinal stem cells (Lgr5+) were cultivated into tiny intestine organoids in vitro by Hans Clevers’ group in the Netherlands in 2009, marking the beginning of the development of organoid cultivation technology. This discovery established the groundwork for organoid research, which quickly gained popularity as a tool in science. Organoids are in vitro-cultured, three-dimensional miniature organs that closely resemble the composition and capabilities of in vivo tissues. They are extensively employed in drug screening, toxicity testing, illness modeling, genetic development research, and customized treatment regimens.
One of the top biotechnology companies, Creative Biogene, provides organoid gene editing services using state-of-the-art CRISPR/Cas9 technology. This innovative technique broadens the potential applications of organoids in scientific research and clinical trials while improving the precision and efficacy of genetic modifications.
